Freeslate’s Biologics Formulation System Selected by Sanofi Pasteur to Improve Efficiency of Formulation Development

Share Article

Sale demonstrates global value of automated, integrated solutions for drug development.

As demonstrated by the adoption of our systems in Europe and across the globe, combinatorial approaches to vaccine formulation development can significantly accelerate productivity.

Freeslate, Inc., the leading provider of high throughput research solutions, today announced that Sanofi Pasteur, the vaccines division of Sanofi, has purchased Freeslate’s Biologics Formulation System, a comprehensive solution for accelerating research in vaccine and protein formulation development. The system automates sample preparation, sample stressing, and formulation analysis, allowing for the development of stable, robust formulations significantly faster with reduced API consumption.

Based on the Freeslate Core Module 3 (CM3) automation platform, the Biologics Formulation System combines liquid dispense and controlled heating/cooling/mixing with new automated measurements of pH, viscosity, and particle counting. Integrated by Freeslate’s Lab Execution and Analysis (LEA) software suite, the system provides intuitive experiment design and allows for the control and data integration of a range of third party analytics including Dynamic Light Scatter (DLS), UV/VIS plate readers, and High Pressure Liquid Chromatography (HPLC), maximizing R&D productivity.

“We are excited to be selected by a global leader in vaccines and are pleased they recognize the value our tools bring to the advancement of formulation development,” said John S. Senaldi, President and CEO of Freeslate. “As demonstrated by the adoption of our systems in Europe and across the globe, combinatorial approaches to vaccine formulation development can significantly accelerate productivity.”

Freeslate has built strong capabilities around automated solutions addressing the complex problems of drug development. The company’s products enable customers to better manage capacity by performing and assessing formulations, minimize later stage reformulations by exploring a broader analytical space early in development, and manage data from orthogonal analytics to help drive informed decision making.

About Freeslate

Freeslate is a privately held company that provides products and related services for high throughput research. Based on its proprietary laboratory automation platforms, high throughput pressure reactors, and integrated Lab Execution and Analysis (LEA) software suite, the company enables dramatic gains in its customers’ productivity and innovation by delivering seamlessly integrated automation solutions. Freeslate leverages its scientific expertise through its team of Ph.D. scientists, engineers, and software developers with directly relevant experience in the industries it serves. Collaborating with customers for more than a decade, the business has provided high throughput research solutions for the pharmaceutical, chemical, and energy industries. The company is headquartered in Sunnyvale, California, with direct sales and service in North America, Europe, and Asia. For more information, visit http://www.freeslate.com.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Mikelle Thatcher
Freeslate, Inc.
+1 (408) 773-4081
Email >
Visit website